XXXX : prevalence and management in lipid clinics.

@entity1 @entity712 @entity28 @entity2299 @entity6 @entity412 @entity165 @entity583 @entity4288
BACKGROUND AND OBJECTIVE: @entity2299 , which is characterized by increased @entity412 levels and reduced HDL @entity165 levels, is underestimated and undertreated in clinical practice. We assessed its prevalence and the achievement of therapeutic objectives for HDL @entity165 and @entity412 levels in @entity1 treated at lipid and vascular risk units in Spain. @entity1 AND METHOD: This was an observational, longitudinal, retrospective, multicenter study performed in 14 autonomous Spanish communities that consecutively included 1828 @entity1 aged >= 18 years who were referred for @entity2299 and vascular risk to 43 lipid clinics accredited by the Spanish Society of @entity4288 . We collected information from the medical records corresponding to 2 visits conducted during 2010 and 2011-12, respectively. RESULTS: Of the 1649 @entity1 who had a lipid profile in the first visit (90.2%), 295 (17.9%) had @entity2299 . The factors associated with @entity2299 were excess weight/ @entity28 , not taking hypolipidemic drugs (statins and/or fibrates), @entity6 , @entity583 and previous @entity712 . Of the 273 (92.5%) @entity1 with @entity2299 that had a lipid profile in the last visit, 44 (16.1%) achieved the therapeutic objectives for HDL @entity165 and @entity412 levels. The predictors of therapeutic success were normal weight and normoglycemia. CONCLUSION: One of every 6 @entity1 treated in lipid and vascular risk units had @entity2299 . The degree to which the therapeutic goals for HDL @entity165 and @entity412 levels were achieved in these @entity1 was very low.
